Previous 10 | Next 10 |
Aurinia Pharma press release (NASDAQ:AUPH): Q1 GAAP EPS of -$0.27 in-line. Revenue of $21.63M (+2276.9% Y/Y) beats by $2.39M. The company maintains net revenue guidance range of $115M-$135M from sales of LUPKYNIS for 2022 vs. consensus of $138.01M. For further details see: Aurinia Pharm...
$21.6 million in net revenue for Q1 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022 Continued increases in LUPKYNIS™ (voclosporin) Patients on Treatment and Patient Start Forms; Steady Conversion Rates and Payor Coverage ...
Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.27 (+32.5% Y/Y) and the consensus Revenue Estimate is $19.24M (+2014.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revision...
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on Tuesday, May 10, 2022. The new numbers for interested partici...
New York, New York--(Newsfile Corp. - May 6, 2022) - Levi & Korsinsky, LLP notifies investors in Aurinia Pharmaceuticals Inc. ("Aurinia Pharmaceuticals Inc." or the "Company") (NASDAQ: AUPH) of a class action securities lawsuit. The lawsuit on behalf of Aurinia Pharmaceuticals Inc. inve...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open. Aurinia’s management team will host a ...
Do you like stocks with triple-digit revenue growth? Here are three companies you might want to dig into. First up is Outset Medical (NASDAQ: OM) , a healthcare company that doubled its sales last year. The next one is Aurinia Pharmaceuticals (NASDAQ: AUPH) ; analysts ar...
The shares of Canadian biotech Aurinia Pharmaceuticals (NASDAQ:AUPH) are trading lower in the morning hours Thursday after RBC Capital Markets lowered its price target, citing Omicron-driven impact for sales of the company’s lupus nephritis therapy, Lupkynis. Ahead of Aurinia’s ...
– Company seeks proposals to create and sustain community-focused programs to support underserved populations with these conditions – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals livi...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...